HOW TEMPUS IS ENABLING THE ACCELERATION OF DRUG DEVELOPMENT
The healthcare industry recognizes the true value of real-world data, especially in disease areas such as oncology, infectious disease, neurology/psychiatry, and cardiology. While it is evident that the world of drug development must root itself in data in order to realize the promise of precision medicine, much of that data is incredibly complex and can be difficult to navigate.
Tempus, a leader in artificial intelligence and precision medicine, is playing a critical role in accelerating drug discovery and development through its recently enhanced, cloud-based data and analytics platform, Lens. Leveraging its vast multimodal data library, Tempus is powering researchers’ and physicians’ efficient profiling and analysis of patient data in Lens to generate valuable insights that spur drug discovery and further personalize patient treatment.
With Lens, oncology research teams in pharma, biotech, and academia can access a suite of data selection, profiling, and bioinformatics tools to identify relevant cohorts, explore patterns, and discover biological insights much more quickly than with bespoke solutions or public data alone. In addition to validating targets with one of the market’s largest multimodal datasets, users of the Lens platform can characterize diseases in a more granular way, analyze co-expression or expression signatures, support trial design for precise patient populations, and work with Tempus’ computational biology and data science teams to launch a multi-scale modeling approach.
Lens is already being utilized by some of the country’s top researchers, pharma companies, and oncologists to advance their precision medicine efforts.
“Visual data exploration in Lens is key to exploring ideas in minutes on large datasets. It helps lower the bar to access the data, and having this capability up front makes it easy to then move to deeper analysis,” said Markus Bauer, Principal Scientist at Boehringer Ingelheim.
“Lens has advanced our research and allowed us to easily leverage Tempus resources in the platform to characterize the genomic landscape of advanced prostate cancer in African American men with the goal to understand the mechanisms behind the disparities seen in clinical outcomes between patients of different ancestries, the findings of which we recently presented at two national meetings,” said Dr. Nicholas Mitsiades, Associate Professor of Medicine at Baylor College of Medicine and Oncologist at the Dan L Duncan Comprehensive Cancer Center. “The ability to filter patients and mutations in Lens offers a more precise look at patient populations and their genomic landscapes. By adding Lens to an arsenal of other products and services, Tempus has made it easy to interact with large datasets and quickly extract meaningful insights.”
Tempus will release ongoing updates to the Lens platform as its database continues to grow. To learn more about Lens and how multi-modal data can uncover new personalized insights, please visit: https://tempus.co/3pirC4B